We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA issued a draft guidance answering commonly asked questions about the Orange Book, the agency’s reference book for generic drug substitutions, including how it deals with patent listings.